Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 3 » Issue 2

The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic

Authors Jeffrey R Strawn, Thomas D Geracioti Jr

Published Date June 2007 Volume 2007:3(2) Pages 237—243

DOI http://dx.doi.org/

Published 8 June 2007

Jeffrey R Strawn1,2,3, Thomas D Geracioti Jr1,2,3

1Department of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, OH, USA; 2Research and 3Psychiatry Services, Cincinnati Veterans Affairs Medical Center Cincinnati, OH, USA

Abstract: A constellation of pharmacologic treatments for generalized anxiety disorder (GAD) have been developed over the past five decades, although each has a number of potential drawbacks in clinical practice. This review addresses one potentially new pharmacologic treatment for generalized anxiety disorder, the gamma-aminobutyric acid analogue pregabalin. We review the mechanism of action, and pharmacokinetic and pharmacodynamic properties of pregabalin as well as the results of 5 double-blind, placebo-controlled trials of pregabalin in the treatment of generalized anxiety disorder (GAD). Based entirely on data from these industry-sponsored (Pfizer), multi-site clinical trials in patients with GAD, pregabalin appears to be generally well tolerated and has rapid onset of action (approximately 1 week), comparable efficacy to benzodiazepines and lower discontinuation rates compared with other pharmacologic treatments. Thus in GAD, a disorder that is often suboptimally responsive to traditional psychotherapeutic and psychopharmacologic interventions – secondary to poor efficacy, tolerability, and/or side-effects – pregabalin may have a primary role in GAD patients, especially in those with certain psychiatric comorbidities or individuals who are on multi-drug regimens for medical comorbidities.

Keywords: GAD, pregabalin, panic attack, anxiety disorders, antidepressant, anxiolytic

Download Article [PDF] 

Readers of this article also read:

A novel chemosynthetic peptide with ß-sheet motif efficiently kills Klebsiella pneumoniae in a mouse model

Tan S, Gan C, Li R, Ye Y, Zhang S, Wu X, Yang YY, Fan W, Wu M

International Journal of Nanomedicine 2015, 10:1045-1059

Published Date: 9 February 2015

Sustained effect of resistance training on blood pressure and hand grip strength following a detraining period in elderly hypertensive women: a pilot study

Nascimento D da C, Tibana RA, Benik FM, Fontana KE, Neto FR, de Santana FS, Santos-Neto L, Silva RAS, Silva AO, Farias DL, Balsamo S, Prestes J

Clinical Interventions in Aging 2014, 9:219-225

Published Date: 20 January 2014

Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo [Corrigendum]

Xiang DX, Zheng Y, Duan W, Li XJ, Yin JJ, Shigdar S, O'Connor ML, Marappan M, Zhao XJ, Miao YQ, Xiang B, Zheng CL

International Journal of Nanomedicine 2013, 8:4703-4704

Published Date: 5 December 2013

Comparison study of ferrofluid and powder iron oxide nanoparticle permeability across the blood–brain barrier

Hoff D, Sheikh L, Bhattacharya S, Nayar S, Webster TJ

International Journal of Nanomedicine 2013, 8:703-710

Published Date: 13 February 2013

Corrigendum

Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1717-1718

Published Date: 26 October 2012

Highly efficient magnetic targeting of mesenchymal stem cells in spinal cord injury

Vaněček V, Zablotskii V, Forostyak S, Růžička J, Herynek V, Babič M, Jendelová P, Kubinová Š, Dejneka A, Syková E

International Journal of Nanomedicine 2012, 7:3719-3730

Published Date: 16 July 2012

Aberrant positioning of a central venous dialysis catheter to reveal a left-sided partial anomalous pulmonary venous connection

Manohar R Chintu, Shammikumar Chinnappa, Sunil Bhandari

Vascular Health and Risk Management 2008, 4:1141-1143

Published Date: 17 September 2008